Fremanezumab: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Fremanezumab. Educational only — not medical advice.
Labeled uses
AJOVY is indicated for: the preventive treatment of migraine in adults, and the preventive treatment of episodic migraine in pediatric patients who are 6 to 17 years of age and who weigh 45 kg or more.
Source: FDA labeling via NIH DailyMed (set 98e344ea…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.